semaglutide supply news november 2025 Novo cuts GLP-1 prices 70%, but revenue could grow in 2026 The weight loss drug boom

*Correspondence: Lishou Xiong, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Microbiome in Health and Disease, a section of the journal Frontiers in Cellular and Infection Microbiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Univariate logistic regression analysis was conducted to identify significant factors of successful weight loss defined as relative weight loss of 5% at 3 months follow-up compared to the baseline visit

Maintaining muscle mass supports metabolic health, physical function, and long-term weight maintenance

2015;66(Suppl 3):103

Initial labs billed separately

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review